Ｍｏｘｉｆｌｏｘａｃｉｎとｇａｒｅｎｏｘａｃｉｎの抗らい菌活性

• 儀同 政一

  国立感染症研究所ハンセン病研究センター

書誌事項

タイトル別名

• In vitro and in vivo activities of moxifloxacin and garenoxacin against Mycobacterium leprae

抄録

Moxifloxacin (MFLX) and garenoxacin (GRNX), new synthetic antibacterial agents, were assessed for in vitro anti-M. leprae activities. The anti-bacterial activities of these two drugs were compared to those of sparfloxacin (SPFX), gatifloxacin (GFLX), levofloxacin (LVFX) and rifampicin (RFP). The anti-M. leprae activity obtained by Buddemeyer system was stronger in order of RFP, MFLX, SPFX, GFLX and GRNX and LUFX.<br>The anti-M. leprae activity of MFLX or GRNX was also examined by the nude mouse footpad method. MFLX completely inhibited the growth of M. leprae inoculated into nude mouse footpads, when given orally at a daily dose of 10mg/kg, while GRNX completely inhibited at a daily dose of 60mg/kg. Both in vitro and in vivo tests indicated that MFLX was equal or superior to SPFX, but GRNX was equipotent to LUFX, in terms of anti-M. leprae activities.

収録刊行物

• 日本ハンセン病学会雑誌

  日本ハンセン病学会雑誌 76 (1), 11-17, 2007

  日本ハンセン病学会

キーワード

• Buddemeyer 法
• ニューキノロン
• ヌードマウス足蹠法

詳細情報

• CRID: 1390282681300365184
• NII論文ID: 10018506943
• NII書誌ID: AN10559906
• DOI: 10.5025/hansen.76.11
• ISSN: 1884314X
• ISSN: 13423681
• Web Site: https://search.jamas.or.jp/link/ui/2007202669
• 本文言語コード: ja
• データソース種別:
  • JaLC
  • Crossref
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可